Compare NTLA & LNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | LNN |
|---|---|---|
| Founded | 2014 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2016 | 1995 |
| Metric | NTLA | LNN |
|---|---|---|
| Price | $13.17 | $105.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 1 |
| Target Price | $20.45 | ★ $113.00 |
| AVG Volume (30 Days) | ★ 3.0M | 133.5K |
| Earning Date | 05-07-2026 | 04-02-2026 |
| Dividend Yield | N/A | ★ 1.44% |
| EPS Growth | ★ 27.43 | 12.81 |
| EPS | N/A | ★ 2.70 |
| Revenue | $67,671,000.00 | ★ $676,368,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $62.75 | $5.91 |
| P/E Ratio | ★ N/A | $38.05 |
| Revenue Growth | ★ 16.92 | 11.41 |
| 52 Week Low | $5.97 | $97.27 |
| 52 Week High | $28.24 | $149.56 |
| Indicator | NTLA | LNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 25.97 |
| Support Level | $12.55 | N/A |
| Resistance Level | $14.32 | $142.35 |
| Average True Range (ATR) | 0.75 | 4.35 |
| MACD | 0.01 | -1.40 |
| Stochastic Oscillator | 65.52 | 32.64 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.